Nature Biotechnology 23, 1327 - 1328 (2005)
Published online: 1 November 2005; | doi:10.1038/nbt1105-1327
Sandoz sues FDA over delay in first biogeneric approvalJeffrey L. Fox
Washington
Officials at the generic branch of Novartis filed a rare type of lawsuit with the US District Court that may affect how the FDA regulates biogenerics.
|
